Golden Road Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$590K Buy
492
+4
+0.8% +$4.09K 0.29% 36
2026
Q1
$449K Buy
488
+41
+9% +$41.6K 0.26% 35
2025
Q4
$480K Buy
447
+16
+4% +$15.3K 0.27% 32
2025
Q3
$329K Buy
431
+49
+13% +$36.5K 0.19% 38
2025
Q2
$298K Buy
382
+21
+6% +$16.3K 0.2% 37
2025
Q1
$298K Buy
361
+7
+2% +$5.83K 0.23% 31
2024
Q4
$273K Buy
354
+3
+0.9% +$2.48K 0.21% 34
2024
Q3
$311K Sell
351
-1
-0.3% -$899 0.24% 33
2024
Q2
$328K Buy
352
+10
+3% +$8K 0.27% 31
2024
Q1
$266K Sell
342
-11
-3% -$7.83K 0.22% 31
2023
Q4
$206K Buy
+353
New +$206K 0.2% 35

Other funds holding LLY

Golden Road Advisors's LLY Position: Q2 2026 in Review

Golden Road Advisors increased its Eli Lilly (LLY) stake by 0.82% in Q2 2026, buying an estimated $4.09K and bringing the position to 492 shares worth $590K. The position accounts for 0.29% of the portfolio, ranked #36.

Golden Road Advisors first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 4,595 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Golden Road Advisors held 492 shares of Eli Lilly worth $590K as of Q2 2026.
  • Golden Road Advisors bought 4 Eli Lilly shares in Q2 2026, an estimated $4.09K.
  • Eli Lilly made up 0.29% of Golden Road Advisors's portfolio in Q2 2026, its #36 holding.
  • Golden Road Advisors first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 4,595 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Golden Road Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.